Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Novartis Ag ADR
(NY:
NVS
)
102.57
-0.12 (-0.12%)
Official Closing Price
Updated: 7:00 PM EDT, May 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Novartis Ag ADR
< Previous
1
2
...
9
10
11
12
13
14
15
16
17
...
38
39
Next >
Stock Market Rally Runs Through Hawkish Fed; Adobe, Lennar, Oracle, UnitedHealth In Focus: Weekly Review
June 16, 2023
Stocks kept powering higher despite, but the Nasdaq is looking extended.
Via
Investor's Business Daily
Eli Lilly Just Lent Its Big Pharma Cachet To Verve's Nascent Gene-Editing Program For $60 Million
June 15, 2023
Eli Lilly inked a deal worth $60 million to get in on a gene-editing drug for elevated lipoprotein A.
Via
Investor's Business Daily
Cryopyrin Associated Periodic Syndrome Clinical Trials | A Drug Pipeline Analysis Report 2023 |Companies – Zydus Cadila, Novartis, Inflazome, Roche, Aclaris Therapeutics
June 15, 2023
Via
AB Newswire
Craniopharyngioma Pipeline, Clinical Trials, and Key Companies|Companies – Novartis, Blaze Bioscience, Bristol Myers Squibb, INSYS Therapeutics, Zafgen
June 15, 2023
Via
AB Newswire
Health Care Company Novartis Announces Merger With Chinook Therapeutics
June 12, 2023
Via
Benzinga
Paroxysmal Nocturnal Hemoglobinuria Market and Epidemiology 2032 by DelveInsight | Roche, Alexion Pharmaceuticals, Novartis, Regeneron Pharmaceuticals, BioCryst Pharmaceuticals, Apellis Pharmaceutical
June 15, 2023
Via
AB Newswire
Investor Opportunities Ahead of Clinical Updates, Says Analyst Initiating Coverage on Ambrx Biopharma with 'Buy' Rating
June 14, 2023
B Riley Securities has initiated Ambrx Biopharma Inc (NASDAQ: AMAM) with a Buy rating and a
Via
Benzinga
Ocular Melanoma Market expected to rise | Companies – Eli Lilly & Co, Spectrum Pharmaceuticals Inc, Novartis AG, Bayer, AstraZeneca plc, Merck, Amgen, Pfizer Inc, Roche, expected to drive market
June 14, 2023
Via
AB Newswire
Hepatocellular Carcinoma Market and Epidemiology 2032: Treatment Therapies, FDA Approvals, Companies and Market Forecasting by DelveInsight | AbbVie, Bayer, Novartis, Bristol-Myers Squibb, Takeda
June 14, 2023
Via
AB Newswire
Exposures
Product Safety
Nasopharyngeal Cancer Pipeline Assessment (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals | Incyte, BeiGene, Klus Pharma, Merck, Roche, Novartis, Akeso Pharma
June 14, 2023
Via
AB Newswire
Exposures
Product Safety
Lupus Nephritis Market to Register Incremental Growth During the Forecast Period (2022-2032), Asserts DelveInsight | Key Companies – Novartis, RemeGen, Roche, Annexon, Argenx, AstraZeneca, Aurinia
June 14, 2023
Via
AB Newswire
Cystic Fibrosis Pipeline, Clinical Trials, and Key Companies|Companies – Krystal Biotech, Vertex Pharmaceuticals, Translate Bio, Novartis, Algi Pharma
June 13, 2023
Via
AB Newswire
Ophthalmoplegia Market expected to rise | Companies – Abbott, Novartis AG, ZEISS International, Valeant Pharmaceuticals International, ALLERGAN, Johnson & Johnson, expected to drive market
June 13, 2023
Via
AB Newswire
KRAS Inhibitors Market to Witness Growth by 2032, Estimates DelveInsight | Novartis, Roche, Genentech, Verastem Oncology, Revolution Medicines, Cardiff Oncology, Immuneering Corporation, Jacobio
June 13, 2023
Via
AB Newswire
Novartis Stock Screams Value After Chinook Therapeutics Buyout
June 13, 2023
Following a buyout of Chinook Therapeutics, Novartis slipped less than 1%. This speaks to the growth potential of Chinook and ongoing value of Novartis stock.
Via
MarketBeat
IgA Nephropathy Pipeline Assessment (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals | Alnylam, RemeGen, Novartis, Visterra/ Otsuka, Vera Therapeutics, Omeros Corp.
June 13, 2023
Via
AB Newswire
Exposures
Product Safety
KDNY Stock Alert: Why Short Seller Muddy Waters Is Betting Against Chinook
June 12, 2023
Chinook Therapeutics is about to be acquired by Novartis. News of this deal hasn't stopped Muddy Waters from betting against KDNY stock.
Via
InvestorPlace
Bone Neoplasms Clinical Trials | A Drug Pipeline Analysis Report 2023 | Companies – Amgen, Novartis, Roche, Merck, Luye Pharma, Bayer, Pfizer.
June 12, 2023
Via
AB Newswire
2022 R&D Spending and Intensity Benchmarks
June 12, 2023
VIRGINIA BEACH, Va. - June 12, 2023 - PRLog -- According to a newly released study from Schonfeld & Associates, Inc., R&D Ratios & Budgets, the pharmaceutical industry continued to be the biggest R&D...
Via
PRLog
Topics
Supply Chain
Exposures
Supply Chain
Opioid-Induced Constipation Market expected to rise | Companies – Cosmo Pharmaceuticals, Shionogi & Co., Merck & Co, Novartis AG, AstraZeneca plc, Bausch Health Companies, expected to boost the market
June 12, 2023
Via
AB Newswire
Food Allergy Market to Witness Upsurge in Growth During the Forecast Period (2022-2032), Examine DelveInsight | Key Companies – Alladapt, Regeneron, InnoUp Farma, Novartis, Genentech, DBV Technologies
June 12, 2023
Via
AB Newswire
Chinook Therapeutics Launches Almost 60% On Novartis' $3.5 Billion Takeover
June 12, 2023
Novartis will pay $3.5 billion to buy the kidney disease-focused biotech company.
Via
Investor's Business Daily
XPeng's New EV Is a Hit, but This Biotech Stock Is Leaving It in the Dust
June 12, 2023
Find out more about two big winners Monday morning.
Via
The Motley Fool
Broadcom Might Receive European Approval For $61B VMware Deal, UBS Closes Credit Suisse Takeover, Illumina CEO Steps Down Amid Activist Investor Carl Icahn's Pressure: Today's Top Stories
June 12, 2023
Reuters Broadcom Most Likely To Receive EU Approval For $61B VMware Merger
Via
Benzinga
Why Is Chinook Therapeutics (KDNY) Stock Up 58% Today?
June 12, 2023
Chinook Therapeutics (KDNY) stock is rocketing higher on Monday after the company announced it's being acquired by Novartis AG (NVS).
Via
InvestorPlace
Hidradenitis Suppurativa Pipeline Assessment (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals | InflaRx, Novartis, ChemoCentryx, AnaptysBio, AbbVie, UCB Biopharma
June 12, 2023
Via
AB Newswire
Exposures
Product Safety
Exploring Novel Approaches to Diabetic Retinopathy Pipeline and Clinical Trials (2023) | Companies – Kodiak Sciences, Novartis, Regenxbio Inc., OcuTerra Therapeutics, Ocular , Bayer, and Others
June 12, 2023
Via
AB Newswire
Breakthrough Therapies and Potential Targets for Complement 3 Glomerulopathy Pipeline Analysis (2023) | Companies – ChemoCentryx, Novartis Pharma, Omeros Corporation, Apellis Pharma, and others
June 12, 2023
Via
AB Newswire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
June 12, 2023
We're starting off the week with a breakdown of the biggest pre-market stock movers traders need to know about for Monday morning!
Via
InvestorPlace
Why Are Chinook Therapeutics Shares Trading Higher Today
June 12, 2023
Novartis AG (NYSE: NVS) has agreed to acquire Chinook Therapeutics Inc (NASDAQ: KDNY) for $40 per share in cash,
Via
Benzinga
< Previous
1
2
...
9
10
11
12
13
14
15
16
17
...
38
39
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.